Journal of magnetic resonance imaging : JMRI
-
Nephrogenic systemic fibrosis (NSF) has been associated with the administration of gadolinium-based contrast agents in patients with severely impaired renal function (SIRF), endstage renal disease (ESRD), or acute renal failure (ARF). Since the vast majority of these patients do not get NSF, it is highly likely that patient factors play a role in its development. Although "free" or dechelated gadolinium is thought by some to be the only trigger of NSF, recent evidence suggests that chelated gadolinium may be important. ⋯ Magn. Reson. Imaging 2009;30:1277-1283. (c) 2009 Wiley-Liss, Inc.
-
To investigate the feasibility of a vessel size imaging (VSI) technique with separate contrast agent injections for evaluation of the vessel caliber in normal tissues and in brain tumors. ⋯ This study suggests that VSI with a dual injection method is a feasible technique for estimating microvascular calibers of normal tissues and brain tumors in clinical scanners.
-
J Magn Reson Imaging · Nov 2009
Comparative StudyHighly accelerated first-pass contrast-enhanced magnetic resonance angiography of the peripheral vasculature: comparison of gadofosveset trisodium with gadopentetate dimeglumine contrast agents.
To investigate the blood pool agent gadofosveset trisodium for first-pass, dynamic peripheral contrast-enhanced magnetic resonance angiography (pMRA), and compare the results with a conventional gadolinium contrast agent. ⋯ First-pass peripheral CE-MRA using gadofosveset trisodium is feasible, yielding image quality comparable to double to triple-dose gadopentetate dimeglumine. Increasing the gadofosveset trisodium dose to 0.05 mmol/kg yields further improvements.